دورية أكاديمية
Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension.
| العنوان: | Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension. |
|---|---|
| المؤلفون: | Stapel JR; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA., Speed JS; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA., Clemmer JS; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA. |
| المصدر: | Canadian journal of physiology and pharmacology [Can J Physiol Pharmacol] 2022 Aug 01; Vol. 100 (8), pp. 828-833. Date of Electronic Publication: 2022 Jun 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1205-7541 (Electronic) Linking ISSN: 00084212 NLM ISO Abbreviation: Can J Physiol Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2011- : Ottawa, ON : Canadian Science Publishing Original Publication: Ottawa, National Research Council of Canada. |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 2*/drug therapy , Hypertension, Pulmonary*/drug therapy , Insulin Resistance*, Animals ; Blood Glucose ; Endothelin Receptor Antagonists/therapeutic use ; Endothelins ; Glycated Hemoglobin/analysis ; Hypoglycemic Agents/therapeutic use ; Insulin ; Mice |
| مستخلص: | Our lab recently reported that the blockade of endothelin-1 (ET-1) receptors attenuates insulin resistance in obese mice; therefore, we hypothesized that patients taking ET-1 receptor antagonists (ERAs) will have improved glycemic control. University of Mississippi Medical Center (2013-2020) electronic health record (EPIC) data were extracted from patients ≥18 years old with a clinical diagnosis of pulmonary hypertension (Food and Drug Administration indication for ERA use) and at least two clinical visits within 2 years. Patients prescribed ERAs ( n = 11) were similar in age (61 ± 14 years vs. 60 ± 14 years), body mass index (BMI) (34 ± 8 kg/m 2 vs. 35 ± 11 kg/m 2 ), diabetes prevalence (73% vs. 80%, p = 0.59), and follow-up time (209 ± 74 days vs. 283 ± 180 days) compared with patients not taking ERAs ( n = 137). There was a small but similar decrease in BMI at follow-up in the ERA (-1.9 ± 3 kg/m 2 ) and control patients (-1.6 ± 5 kg/m 2 ). At follow-up, hemoglobin A1c (HbA1c) significantly decreased -12% ± 11% of baseline in patients taking ERAs, while this did not occur in the control patients (2% ± 20% increase in HbA1c). In the whole population, baseline HbA1c and ERA prescription predicted the fall in HbA1c, while there was no significant association with demographics, diabetes prevalence, and diabetic treatment. These data suggest a potential role of ET-1 in promoting insulin resistance and warrant further investigation into using these drugs for glycemic control. |
| References: | Blood Press. 2017 Jun;26(3):139-149. (PMID: 27808564) J Am Soc Nephrol. 2014 May;25(5):1083-93. (PMID: 24722445) Cochrane Database Syst Rev. 2018 Oct 29;10:CD012661. (PMID: 30371961) Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H689-95. (PMID: 21666117) QJM. 2001 Jun;94(6):321-6. (PMID: 11391030) Hypertens Res. 2017 Dec;40(12):947-963. (PMID: 28978986) Biochem Biophys Res Commun. 1996 Oct 23;227(3):694-9. (PMID: 8885996) Prim Care. 2016 Mar;43(1):121-35, ix. (PMID: 26896205) Lancet. 2019 May 11;393(10184):1937-1947. (PMID: 30995972) PLoS One. 2011;6(10):e26063. (PMID: 22016812) N Engl J Med. 2021 Jun 10;384(23):2219-2228. (PMID: 34107181) Clin Sci (Lond). 2021 Jul 30;135(14):1773-1789. (PMID: 34278410) Hypertension. 2019 Aug;74(2):323-330. (PMID: 31177906) Surg Obes Relat Dis. 2019 Jul;15(7):1044-1050. (PMID: 31147283) |
| معلومات مُعتمدة: | K99 MD014738 United States MD NIMHD NIH HHS; P20 GM104357 United States GM NIGMS NIH HHS; R00 HL127178 United States HL NHLBI NIH HHS; R01 DK124327 United States DK NIDDK NIH HHS |
| فهرسة مساهمة: | Keywords: HbA1c; endothelin-1; endothéline 1; glucose; insulin resistance; résistance à l’insuline |
| المشرفين على المادة: | 0 (Blood Glucose) 0 (Endothelin Receptor Antagonists) 0 (Endothelins) 0 (Glycated Hemoglobin A) 0 (Hypoglycemic Agents) 0 (Insulin) |
| تواريخ الأحداث: | Date Created: 20220606 Date Completed: 20220914 Latest Revision: 20230121 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9851169 |
| DOI: | 10.1139/cjpp-2022-0132 |
| PMID: | 35658576 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1205-7541 |
|---|---|
| DOI: | 10.1139/cjpp-2022-0132 |